Logo

Cynvenio Biosystems PD-L1 Expression Assay

Aug 11, 2017

Cynvenio Biosystems has launched its second-generation PD-L1 expression test. The blood test has improved analytic performance compared to the first-generation test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from blood. Cynvenio is offering the test from its CLIA/CAP laboratory in California with a three- to seven-day turnaround time. The test is also available to all Cynvenio customers running its LiquidBiopsy platform and workflow, the company said.

Breaking News
The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.